Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Romano CD, Slota C, Bratlee-Whitaker E, Edwards T, Herring WL, McLeod L, Callahan L, Bullok K, Raimundo K, Taylor J, Taylor G, Kremer I, Monks D, Lappin D, Frangiosa T, Gnanasakthy K, Goss D, Comer M, Paulsen R, Hartry A, DiBenedetti D. Measuring "What Matters Most™" to individuals living with Alzheimer's disease and care partners: a conceptual model of Alzheimer's disease. Poster presented at the AAIC 2023 Conference; July 16, 2023. Amsterdam, Netherlands.

Vincendeau S, Jiang S, Varghese D, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Scailteux LM, Hussain A. Non-metastatic castration-resistant prostate cancer treated with androgen receptor axis targeting agents - French trends. Clin Onco. 2022 Dec 2;6(15):1-9.

Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials. 2022 Sep;120:106860. doi: 10.1016/j.cct.2022.106860

Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AEs) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the Virtual Journal of Managed Care & Specialty Pharmacy 2020 Conference; October 2020. [abstract] J Manag Care Spec Pharm. 2020 Oct; 26(10-a Suppl):S89. Previously presented at the 2020 Virtual ISPOR Asia Pacific Conference.

Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AE) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the 2020 Virtual ISPOR Asia Pacific Conference; September 10, 2020. [abstract] Value in Health Regional Issues. 2020 Sep 1; 22(Supplement):S4-5.